Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib)...
Hence then, the article about fda approves lumakras sotorasib in combination with vectibix panitumumab for chemorefractory kras g12c mutated metastatic colorectal cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER )
Also on site :
- McDonald’s is about to report earnings. Here’s what to expect
- Germany’s new militarization: Revival of the spirit or blatant revanchism? (by Dmitry Medvedev)
- France introduces one‑euro canteen meals for all students